Metformin was proposed to act as a modifier of alternative mRNA splicing of a subset of genes mis-splicing in myotonic dystrophy type 1 by activation of AMPK and downregulation of the expression of the RNA-binding protein 3 (RBM3) [98]. Here, RBM3 is linked to myotonic dystrophy type 1.